Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Change in Account Payables (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Change in Account Payables for 17 consecutive years, with -$4.2 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 281.82% to -$4.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.4 million through Dec 2025, down 129.79% year-over-year, with the annual reading at -$1.4 million for FY2025, 129.79% down from the prior year.
  • Change in Account Payables for Q4 2025 was -$4.2 million at Myriad Genetics, down from -$800000.0 in the prior quarter.
  • The five-year high for Change in Account Payables was $14.0 million in Q4 2021, with the low at -$12.9 million in Q3 2021.
  • Average Change in Account Payables over 5 years is $278947.4, with a median of -$800000.0 recorded in 2025.
  • The sharpest move saw Change in Account Payables skyrocketed 1266.67% in 2021, then tumbled 1166.67% in 2022.
  • Over 5 years, Change in Account Payables stood at $14.0 million in 2021, then tumbled by 117.14% to -$2.4 million in 2022, then crashed by 145.83% to -$5.9 million in 2023, then skyrocketed by 81.36% to -$1.1 million in 2024, then crashed by 281.82% to -$4.2 million in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$4.2 million, -$800000.0, and $3.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.